Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology guideline): American Society of Clinical Oncology clinical practice guideline endorsement

Journal of Clinical Oncology

Volumn 34, Issue 16, 2016, Pages 1945-1952

  Milowsky, Matthew I ^a   Bryan Rumble, R ^b   Booth, Christopher M ^c   Gilligan, Timothy ^e   Eapen, Libni J ^d   Hauke, Ralph J ^f   Boumansour, Pat ^g   Lee, Cheryl T ^h  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c QUEEN S UNIVERSITY   (Canada)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

^e LERNER RESEARCH INSTITUTE   (United States)

^f Nebraska Cancer Specialists   (United States)

^g University of Michigan ^*  (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMORADIOTHERAPY; CLINICAL PRACTICE; CYSTECTOMY; HUMAN; MEDICAL SOCIETY; METHODOLOGY; MUSCLE INVASIVE BLADDER CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; METASTASIS; PATHOLOGY; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CISPLATIN; CYSTECTOMY; HUMANS; NEOPLASM METASTASIS; PRACTICE GUIDELINES AS TOPIC; URINARY BLADDER NEOPLASMS;

EID: 84973277821     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.9797     Document Type: Article

References (11)

1. Witjes JA, Compérat E, Cowan NC, et al: EAU guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2013 guidelines. Eur Urol 65:778-792, 2014
2. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65:5-29, 2015
3. Sternberg CN, Skoneczna I, Kerst JM, et al: Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): An intergroup, open-label, randomised phase 3 trial. Lancet Oncol 16:76-86, 2015
4. Rödel C, Weiss C: Organ-sparing multimodality treatment for muscle-invasive bladder cancer: Can we continue to ignore the evidence? J Clin Oncol 32: 3787-3788, 2014
5. Galsky MD, Hahn NM, Rosenberg J, et al: Treatment of patients with metastatic urothelial cancer "unfit" for cisplatin-based chemotherapy. J Clin Oncol 29:2432-2438, 2011
6. De Santis M, Bellmunt J, Mead G, et al: Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 30:191-199, 2012
7. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315-322, 2014
8. Powles T, Eder JP, Fine GD, et al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558-562, 2014
9. Henry DH, Costa L, Goldwasser F, et al: Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29: 1125-1132, 2011
10. Rosen LS, Gordon D, Tchekmedyian S, et al: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157, 2003
11. Zaghloul MS, Boutrus R, El-Hossieny H, et al: A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 15:382-389, 2010